LiveOne, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LiveOne, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $114.41M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $118.44M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $99.61M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $117.02M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $65.23M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $38.66M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $33.70M | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | $7.20M | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | $225.0K | Jun 29, 2018 |
| FY2015 | Mar 31, 2015 | $7.44M | Jul 14, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $114.41M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $118.44M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $99.61M | Jul 1, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Mar 31, 2015 | $6.34M | Jul 14, 2015 |
| FY2015 | Mar 31, 2014 | $5.94M | Jul 14, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($18.71M) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | ($11.97M) | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | ($10.02M) | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | ($43.91M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($41.82M) | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | ($38.93M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($37.76M) | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | ($23.34M) | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | ($14.25M) | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | ($3.75M) | Jun 14, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($18.06M) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | ($4.67M) | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | ($2.18M) | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | ($37.85M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($29.37M) | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | ($36.00M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($33.89M) | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | ($14.88M) | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | ($5.49M) | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | ($3.98M) | Jun 14, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.48M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $4.68M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $5.14M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $8.09M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $9.68M | Jun 29, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Mar 31, 2017 | $5.35M | Jun 14, 2017 |
| FY2017 | Mar 31, 2016 | $3.62M | Jun 14, 2017 |
| FY2016 | Mar 31, 2015 | $2.72M | Jul 19, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.37M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $6.85M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | ($3.84M) | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | ($9.12M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($9.51M) | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | ($4.89M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($5.77M) | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | ($5.73M) | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | ($3.12M) | Jun 29, 2018 |
| FY2013 | Apr 30, 2013 | ($698.2K) | Jul 29, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.05M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $3.04M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $2.44M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $3.74M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $3.21M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $2.58M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $2.53M | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | $49.0K | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | $19.0K | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | $58.0K | Jun 14, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $40.52M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $63.86M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $65.89M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $76.82M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $85.77M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $54.12M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $58.90M | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | $68.03M | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | $1.56M | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | $5.22M | Jun 14, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $48.93M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $57.31M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $62.07M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $87.74M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $77.63M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $61.25M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $49.44M | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | $29.63M | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | $4.96M | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | $4.99M | Jun 14, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($17.78M) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | ($8.74M) | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | ($1.01M) | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | ($10.92M) | Jun 29, 2023 |
| FY2023 | Mar 31, 2021 | $8.14M | Jun 29, 2023 |
| FY2022 | Mar 31, 2020 | ($7.13M) | Jun 29, 2022 |
| FY2021 | Mar 31, 2019 | $9.46M | Jul 14, 2021 |
| FY2020 | Mar 31, 2018 | $38.40M | Jun 26, 2020 |
| FY2019 | Mar 31, 2017 | ($3.41M) | Jun 24, 2019 |
| FY2018 | Mar 31, 2016 | $231.0K | Jun 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $21.71M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $23.38M | Jul 15, 2025 |
| FY2025 | Mar 31, 2023 | $23.38M | Jul 15, 2025 |
| FY2024 | Mar 31, 2022 | $23.38M | Jul 1, 2024 |
| FY2022 | Mar 31, 2021 | $22.62M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $9.67M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $9.67M | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | $5.38M | Jun 24, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($265.12M) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | ($238.98M) | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | ($224.27M) | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | ($213.85M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($169.94M) | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | ($128.12M) | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | ($89.19M) | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | ($51.43M) | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | ($28.10M) | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | ($13.85M) | Jun 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.12M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $6.99M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $8.41M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | $12.89M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $18.64M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | $5.70M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | $13.70M | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | $10.29M | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | $1.48M | Jun 29, 2018 |
| FY2018 | Mar 31, 2016 | $37.0K | Jun 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Mar 31, 2022 | $28.06M | Jun 29, 2022 |
| FY2020 | Mar 31, 2020 | $9.23M | Jun 26, 2020 |
| FY2020 | Mar 31, 2019 | $12.40M | Jun 26, 2020 |
| FY2017 | Mar 31, 2017 | $288.4K | Jun 14, 2017 |
| FY2017 | Mar 31, 2016 | $110.3K | Jun 14, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Jun 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | 0 | Jun 29, 2023 |
| FY2023 | Mar 31, 2022 | 0 | Jun 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 96.77M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | 92.49M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | 87.44M | Jul 1, 2024 |
| FY2023 | Mar 31, 2022 | 82.55M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 76.81M | Jun 29, 2022 |
| FY2021 | Mar 31, 2020 | 58.98M | Jul 14, 2021 |
| FY2020 | Mar 31, 2019 | 52.28M | Jun 26, 2020 |
| FY2019 | Mar 31, 2018 | 51.43M | Jun 24, 2019 |
| FY2018 | Mar 31, 2017 | 34.67B | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | 92.00M | Jun 14, 2017 |